Whitehawk Q2 Loss Narrows to $16.6M, Crushing Estimates on Lower R&D Costs
WHWK has more than doubled off its 52-week low of $1.57.
Summary
Whitehawk's Q2 net loss shrank to $16.64M, well below the $22.29M consensus, driven by the absence of a $38M license fee that inflated R&D costs a year ago. Operating loss also beat handily at $18.11M vs. $23.48M expected. This follows the $87.5M private placement in May and the ADC pipeline expansion, showing the company is managing costs while advancing its oncology programs. The beat reinforces the cash runway into 2028 and supports the bullish analyst consensus. With shares at $4.07 pre-market, the $7.50 median target implies significant upside if execution continues.
At the time of this announcement, WHWK was trading at $4.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.9M. The 52-week trading range was $1.57 to $5.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.